{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T08:00:50Z","timestamp":1792051250000,"version":"4.4.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T00:00:00Z","timestamp":1675987200000},"content-version":"am","delay-in-days":315,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000066","name":"National Institute of Environmental Health Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000066","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AES12013"],"award-info":[{"award-number":["AES12013"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["FDA IAG # 224-17-0502"],"award-info":[{"award-number":["FDA IAG # 224-17-0502"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology Letters"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.toxlet.2022.01.011","type":"journal-article","created":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T01:08:12Z","timestamp":1643418492000},"page":"22-30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Toxicity of high-molecular-weight polyethylene glycols in Sprague Dawley rats"],"prefix":"10.1016","volume":"359","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4687-5043","authenticated-orcid":false,"given":"Jia-Long","family":"Fang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle M.","family":"Vanlandingham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick A.","family":"Beland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Felton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mackean P.","family":"Maisha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg R.","family":"Olson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph E.","family":"Patton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy S.","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gon\u00e7alo","family":"Gamboa da Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.toxlet.2022.01.011_bib0005","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jconrel.2013.07.026","article-title":"The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage","volume":"172","author":"Abu Lila","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.toxlet.2022.01.011_bib0010","series-title":"PEGylated Protein Drugs: Basic Science and Clinical Applications","first-page":"147","article-title":"The occurrence, induction, specificity and potential effect of antibodies against poly(ethylene glycol)","author":"Armstrong","year":"2009"},{"issue":"1","key":"10.1016\/j.toxlet.2022.01.011_bib0015","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/cncr.22739","article-title":"Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients","volume":"110","author":"Armstrong","year":"2007","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.toxlet.2022.01.011_bib0020","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.drudis.2014.06.002","article-title":"Pharmacokinetics, metabolism and distribution of PEGs and PEGylated proteins: quo vadis?","volume":"19","author":"Baumann","year":"2014","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.toxlet.2022.01.011_bib0025","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ejps.2015.10.020","article-title":"Pharmacokinetics, tissue distribution and excretion of 40 kDa PEG and PEGylated rFVIII (N8-GP) in rats","volume":"87","author":"Bj\u00f8rnsdottir","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.toxlet.2022.01.011_bib0030","series-title":"Nonparametric Analysis of Longitudinal Data in Factorial Experiments","author":"Brunner","year":"2002"},{"issue":"10","key":"10.1016\/j.toxlet.2022.01.011_bib0035","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S0169-409X(03)00108-X","article-title":"Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates","volume":"55","author":"Caliceti","year":"2003","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.toxlet.2022.01.011_bib0040","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3390\/pharmaceutics12010015","article-title":"Both IgM and IgG antibodies against polyethylene glycol can alter the biological activity of methoxy polyethylene glycol-epoetin beta in mice","volume":"12","author":"Chang","year":"2019","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.toxlet.2022.01.011_bib0045","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1021\/bc980143z","article-title":"Accelerated clearance of polyethylene glycol-modified proteins by anti-polyethylene glycol IgM","volume":"10","author":"Cheng","year":"1999","journal-title":"Bioconjug. Chem."},{"issue":"2","key":"10.1016\/j.toxlet.2022.01.011_bib0050","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1021\/bc990147j","article-title":"Efficient clearance of poly(ethylene glycol)-modified immunoenzyme with anti-PEG monoclonal antibody for prodrug cancer therapy","volume":"11","author":"Cheng","year":"2000","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.toxlet.2022.01.011_bib0055","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables","volume":"B34","author":"Cox","year":"1972","journal-title":"J. R. Stat. Soc."},{"issue":"1","key":"10.1016\/j.toxlet.2022.01.011_bib0060","doi-asserted-by":"crossref","first-page":"414","DOI":"10.2903\/j.efsa.2007.414","article-title":"Opinion of the Scientific Panel on food additives, flavourings, processing aids and materials in contact with food (AFC) related to an application on the use of polyethylene glycol (PEG) as a film coating agent for use in food supplement products","volume":"5","author":"EFSA","year":"2007","journal-title":"EFSA J."},{"issue":"4","key":"10.1016\/j.toxlet.2022.01.011_bib0065","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1039\/C4TX00152D","article-title":"Dose\u2013response assessment of the dermal toxicity of triclosan in B6C3F1 mice","volume":"4","author":"Fang","year":"2015","journal-title":"Toxicol. Res."},{"key":"10.1016\/j.toxlet.2022.01.011_bib0070","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.toxrep.2020.12.022","article-title":"Flow cytometry analysis of anti-polyethylene glycol antibodies in human plasma","volume":"8","author":"Fang","year":"2021","journal-title":"Toxicol. Rep."},{"issue":"1\u20132","key":"10.1016\/j.toxlet.2022.01.011_bib0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tox.2005.06.001","article-title":"Safety assessment on polyethylene glycols (PEGs) and their derivatives as used in cosmetic products","volume":"214","author":"Fruijtier-P\u00f6lloth","year":"2005","journal-title":"Toxicology"},{"issue":"1","key":"10.1016\/j.toxlet.2022.01.011_bib0080","doi-asserted-by":"crossref","first-page":"R12","DOI":"10.1186\/ar1861","article-title":"Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase","volume":"8","author":"Ganson","year":"2006","journal-title":"Arthritis Res. Ther."},{"issue":"5","key":"10.1016\/j.toxlet.2022.01.011_bib0085","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/j.jaci.2015.10.034","article-title":"Pre-existing anti-polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer","volume":"137","author":"Ganson","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"issue":"11","key":"10.1016\/j.toxlet.2022.01.011_bib0090","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1517\/17425247.2012.720969","article-title":"Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents","volume":"9","author":"Garay","year":"2012","journal-title":"Expert Opin. Drug Deliv."},{"issue":"2","key":"10.1016\/j.toxlet.2022.01.011_bib0095","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar4500","article-title":"Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients","volume":"16","author":"Hershfield","year":"2014","journal-title":"Arthritis Res. Ther."},{"issue":"11","key":"10.1016\/j.toxlet.2022.01.011_bib0100","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.7150\/thno.22164","article-title":"Pre-existing anti-polyethylene glycol antibody reduces the therapeutic efficacy and pharmacokinetics of PEGylated liposomes","volume":"8","author":"Hsieh","year":"2018","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.toxlet.2022.01.011_bib0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/pharmaceutics3010001","article-title":"Anti-PEG IgM response against PEGylated liposomes in mice and rats","volume":"3","author":"Ichihara","year":"2011","journal-title":"Pharmaceutics"},{"issue":"6","key":"10.1016\/j.toxlet.2022.01.011_bib0110","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1177\/0192623318791801","article-title":"Scientific and regulatory policy committee points to consider: histopathologic evaluation in safety assessment studies for PEGylated pharmaceutical products","volume":"46","author":"Irizarry Rovira","year":"2018","journal-title":"Toxicol. Pathol."},{"issue":"1","key":"10.1016\/j.toxlet.2022.01.011_bib0115","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jconrel.2006.01.005","article-title":"Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes","volume":"112","author":"Ishida","year":"2006","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.toxlet.2022.01.011_bib0120","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jconrel.2007.05.015","article-title":"PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner","volume":"122","author":"Ishida","year":"2007","journal-title":"J. Control. Release"},{"issue":"7","key":"10.1016\/j.toxlet.2022.01.011_bib0125","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1177\/0192623315591171","article-title":"PEGylated biopharmaceuticals: current experience and considerations for nonclinical development","volume":"43","author":"Ivens","year":"2015","journal-title":"Toxicol. Pathol."},{"issue":"4 Suppl","key":"10.1016\/j.toxlet.2022.01.011_bib0130","doi-asserted-by":"crossref","first-page":"87S","DOI":"10.1177\/0192623312439125","article-title":"Proliferative and nonproliferative lesions of the rat and mouse central and peripheral nervous systems","volume":"40","author":"Kaufmann","year":"2012","journal-title":"Toxicol. Pathol."},{"issue":"10","key":"10.1016\/j.toxlet.2022.01.011_bib0135","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1124\/dmd.115.064337","article-title":"Disposition of basal insulin peglispro compared with 20-kDa polyethylene glycol in rats following a single intravenous or subcutaneous dose","volume":"43","author":"Knadler","year":"2015","journal-title":"Drug Metab. Dispos."},{"issue":"28","key":"10.1016\/j.toxlet.2022.01.011_bib0140","doi-asserted-by":"crossref","first-page":"5424","DOI":"10.1016\/j.chroma.2009.05.043","article-title":"Size exclusion chromatography with Corona charged aerosol detector for the analysis of polyethylene glycol polymer","volume":"1216","author":"Kou","year":"2009","journal-title":"J. Chromatogr. A"},{"issue":"2","key":"10.1016\/j.toxlet.2022.01.011_bib0145","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/0003-2697(92)90460-O","article-title":"Detection and molecular weight determination of polyethylene glycol-modified hirudin by staining after sodium dodecyl sulfate-polyacrylamide gel electrophoresis","volume":"200","author":"Kurf\u00fcrst","year":"1992","journal-title":"Anal. Biochem."},{"issue":"1\u20132","key":"10.1016\/j.toxlet.2022.01.011_bib0150","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.chroma.2004.06.005","article-title":"Separation of polyethylene glycols and their amino-substituted derivatives by high-performance gel filtration chromatography at low ionic strength with refractive index detection","volume":"1046","author":"Liu","year":"2004","journal-title":"J. Chromatogr. A"},{"issue":"7","key":"10.1016\/j.toxlet.2022.01.011_bib0155","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1021\/acs.molpharmaceut.5b00144","article-title":"Anti-PEG IgM is a major contributor to the accelerated blood clearance of polyethylene glycol-conjugated protein","volume":"12","author":"Mima","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.toxlet.2022.01.011_bib0160","first-page":"45","article-title":"Conjugates of peptides and proteins to polyethylene glycols","volume":"283","author":"Morpurgo","year":"2004","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.toxlet.2022.01.011_bib0165","series-title":"Coagulation Factor IX (Recombinant), GlycoPEGylated N9-GP, BLA125611 FDA Briefing Document (April 4, 2017)","author":"NovoNordisk","year":"2017"},{"issue":"6","key":"10.1016\/j.toxlet.2022.01.011_bib0170","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1016\/j.jaci.2016.04.058","article-title":"Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer","volume":"138","author":"Povsic","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"issue":"2","key":"10.1016\/j.toxlet.2022.01.011_bib0175","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000233309","article-title":"Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol modified proteins","volume":"70","author":"Richter","year":"1983","journal-title":"Int. Arch. Allergy Appl. Immunol."},{"issue":"7","key":"10.1016\/j.toxlet.2022.01.011_bib0180","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1177\/0192623312474726","article-title":"High molecular weight polyethylene glycol cellular distribution and PEG-associated cytoplasmic vacuolation is molecular weight dependent and does not require conjugation to proteins","volume":"41","author":"Rudmann","year":"2013","journal-title":"Toxicol. Pathol."},{"issue":"7","key":"10.1016\/j.toxlet.2022.01.011_bib0185","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1007\/s11095-013-1067-7","article-title":"The immunogenicity of polyethylene glycol: facts and fiction","volume":"30","author":"Schellekens","year":"2013","journal-title":"Pharm. Res."},{"issue":"5","key":"10.1016\/j.toxlet.2022.01.011_bib0190","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1080\/01926230701595300","article-title":"Society of Toxicologic Pathology position paper: organ weight recommendations for toxicology studies","volume":"35","author":"Sellers","year":"2007","journal-title":"Toxicol. Pathol."},{"issue":"8","key":"10.1016\/j.toxlet.2022.01.011_bib0195","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1248\/bpb.b12-00276","article-title":"Intravenous administration of polyethylene glycol-coated (PEGylated) proteins and PEGylated adenovirus elicits an anti-PEG immunoglobulin M response","volume":"35","author":"Shimizu","year":"2012","journal-title":"Biol. Pharm. Bull."},{"issue":"1","key":"10.1016\/j.toxlet.2022.01.011_bib0200","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1080\/14686996.2019.1590126","article-title":"Toxicity and immunogenicity concerns related to PEGylated-micelle carrier systems: a review","volume":"20","author":"Shiraishi","year":"2019","journal-title":"Sci. Technol. Adv. Mater."},{"issue":"1","key":"10.1016\/j.toxlet.2022.01.011_bib0205","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/0003-2697(80)90492-3","article-title":"A method for the estimation of polyethylene glycol in plasma protein fractions","volume":"107","author":"Sims","year":"1980","journal-title":"Anal. Biochem."},{"issue":"1","key":"10.1016\/j.toxlet.2022.01.011_bib0210","first-page":"37","article-title":"Repeated injections of PEG-PE liposomes generate anti-PEG antibodies","volume":"10","author":"\u015aroda","year":"2005","journal-title":"Cell. Mol. Biol. Lett."},{"issue":"1","key":"10.1016\/j.toxlet.2022.01.011_bib0215","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/hae.12762","article-title":"Safety of PEGylated recombinant human full-length coagulation factor VIII (BAX 855) in the overall context of PEG and PEG conjugates","volume":"22","author":"Stidl","year":"2016","journal-title":"Haemophilia"},{"issue":"7","key":"10.1016\/j.toxlet.2022.01.011_bib0220","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/jama.2011.1169","article-title":"Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials","volume":"306","author":"Sundy","year":"2011","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.toxlet.2022.01.011_bib0225","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.xphs.2015.11.015","article-title":"PEGylation of biopharmaceuticals: a review of chemistry and nonclinical safety information of approved drugs","volume":"105","author":"Turecek","year":"2016","journal-title":"J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.toxlet.2022.01.011_bib0230","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1124\/dmd.106.012419","article-title":"PEGylated proteins: evaluation of their safety in the absence of definitive metabolism studies","volume":"35","author":"Webster","year":"2007","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.toxlet.2022.01.011_bib0235","series-title":"PEGylated Protein Drugs: Basic Science and Clinical Applications","first-page":"127","article-title":"PEG and PEG conjugates toxicity: towards an understanding of the toxicity of PEG and its relevance to PEGylated biologicals","author":"Webster","year":"2009"},{"issue":"3","key":"10.1016\/j.toxlet.2022.01.011_bib0240","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/jps.2600840316","article-title":"Fate of water-soluble polymers administered via different routes","volume":"84","author":"Yamaoka","year":"1995","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.toxlet.2022.01.011_bib0245","first-page":"2891","article-title":"Repeated injection of PEGylated solid lipid nanoparticles induces accelerated blood clearance in mice and beagles","volume":"7","author":"Zhao","year":"2012","journal-title":"Int. J. Nanomed."}],"container-title":["Toxicology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378427422000236?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378427422000236?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T05:24:58Z","timestamp":1759901098000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378427422000236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":49,"alternative-id":["S0378427422000236"],"URL":"https:\/\/doi.org\/10.1016\/j.toxlet.2022.01.011","relation":{},"ISSN":["0378-4274"],"issn-type":[{"value":"0378-4274","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toxicity of high-molecular-weight polyethylene glycols in Sprague Dawley rats","name":"articletitle","label":"Article Title"},{"value":"Toxicology Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.toxlet.2022.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}